BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference |
| December 12, 2018 | December 2018 Bond Updates |
|
BERGEN, Norway, Dec 12 2018 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces that the Company will be presenting key results from... |
| View more at: https://www.prnewswire.com:443/news-releases/bergenbio-presents-key-results-from-phii-programme-with-selective-axl-inhibitor-bemcentinib-at-dnbs-9th-annual-nordic-healthcare-conference-300764032.html |
| Related News |
|